Ovid Therapeutics Inc. (OVID)
Market Cap | 54.87M |
Revenue (ttm) | 473,535 |
Net Income (ttm) | -50.68M |
Shares Out | 70.94M |
EPS (ttm) | -0.73 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 762,687 |
Open | 0.873 |
Previous Close | 0.862 |
Day's Range | 0.773 - 0.883 |
52-Week Range | 0.680 - 4.139 |
Beta | 0.58 |
Analysts | Strong Buy |
Price Target | 4.04 (+422.37%) |
Earnings Date | Aug 2, 2024 |
About OVID
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex an... [Read more]
Financial Performance
In 2023, OVID's revenue was $391,695, a decrease of -73.93% compared to the previous year's $1.50 million. Losses were -$52.34 million, -3.38% less than in 2022.
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for OVID stock is "Strong Buy." The 12-month stock price forecast is $4.04, which is an increase of 422.37% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/e/u/press5-2506426.jpg)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ovid Therapeutics Inc. - OVID
NEW YORK , July 2, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ovid Therapeutics Inc. ("Ovid" or the "Company") (NASDAQ: OVID). Such investors are advised to c...
![](https://cdn.snapi.dev/images/v1/q/a/press2-2504510.jpg)
Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888/GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous Malformations
NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditio...
![](https://cdn.snapi.dev/images/v1/g/i/press18-2503968.jpg)
Investors who lost money on Ovid Therapeutics Inc. should contact Levi & Korsinsky about an ongoing investigation - OVID
NEW YORK, NY / ACCESSWIRE / June 30, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Ovid Therapeutics Inc. ("Ovid") (NASDAQ:OVID) concerning possible violations o...
![](https://cdn.snapi.dev/images/v1/g/a/press7-2503951.jpg)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ovid Therapeutics Inc. - OVID
NEW YORK, June 30, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ovid Therapeutics Inc. (“Ovid” or the “Company”) (NASDAQ: OVID). Such investors are advised ...
![](https://cdn.snapi.dev/images/v1/g/w/press4-2501602.jpg)
OVID ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you Lost Money on your Ovid Therapeutics Inc. Investment
NEW YORK, NY / ACCESSWIRE / June 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Ovid Therapeutics Inc. ("Ovid") (NASDAQ:OVID) concerning possible violations o...
![](https://cdn.snapi.dev/images/v1/m/2/press14-2498479.jpg)
Lost Money on Ovid Therapeutics Inc.(OVID)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky
NEW YORK, NY / ACCESSWIRE / June 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Ovid Therapeutics Inc. ("Ovid") (NASDAQ:OVID) concerning possible violations o...
![](https://cdn.snapi.dev/images/v1/n/a/biotech24-2482033.jpg)
What's Going On With Ovid Therapeutics After Takeda's Two Phase 3 Epilepsy Studies Fail?
Monday, Takeda Pharmaceutical Co Ltd TAK announced topline data from its SKYLINE and SKYWAY Phase 3 studies of Soticlestat (TAK-935) for the treatment of Dravet syndrome (DS) and Lennox-Gastaut syndro...
![](https://cdn.snapi.dev/images/v1/7/k/press1-2481536.jpg)
Ovid Therapeutics Reports on Takeda's Announcement of Phase 3 Topline Study Results for Soticlestat
NEW YORK, June 17, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to meaningfully improving the lives of people affected by rare epilepsies and b...
![](https://cdn.snapi.dev/images/v1/w/y/press15-2429162.jpg)
Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results
NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to meaningfully improving the lives of people affected by rare epilepsies and br...
![](https://cdn.snapi.dev/images/v1/8/w/conf6-2426536.jpg)
Ovid Therapeutics to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference
NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of ...
![](https://cdn.snapi.dev/images/v1/r/q/conf4-2356198.jpg)
Ovid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
NEW YORK, April 04, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to meaningfully improving the lives of people affected by rare epilepsies and ...
![](https://cdn.snapi.dev/images/v1/v/3/press20-2315235.jpg)
Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results
NEW YORK, March 08, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to meaningfully improving the lives of people affected by rare epilepsies and ...
![](https://cdn.snapi.dev/images/v1/y/t/conf2-2298258.jpg)
Ovid Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference
NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of...
![](https://cdn.snapi.dev/images/v1/q/w/conf9-2261744.jpg)
Ovid Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
NEW YORK, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of...
![](https://cdn.snapi.dev/images/v1/u/k/conf5-2179515.jpg)
Ovid Therapeutics to Present Five Abstracts Supporting its Epilepsy Programs at the 77th American Epilepsy Society Annual Meeting (2023)
NEW YORK, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of...
![](https://cdn.snapi.dev/images/v1/n/7/press7-2138740.jpg)
Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Updates
NEW YORK, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare epilepsies...
![](https://cdn.snapi.dev/images/v1/m/r/press9-2108487.jpg)
Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid's Cash Runway into 2026
NEW YORK and SAN DIEGO, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to developing medicines that transform the lives of people with r...
![](https://cdn.snapi.dev/images/v1/9/7/conf12-2096546.jpg)
Ovid Therapeutics to Present at the Jefferies Biotech CNS/Neuro Summit
NEW YORK, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and ...
![](https://cdn.snapi.dev/images/v1/h/8/press13-2077597.jpg)
Ovid Therapeutics to Host Investor Event - R&D Day on Monday, October 2, 2023
NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and...
![](https://cdn.snapi.dev/images/v1/q/r/conf4-2070676.jpg)
Ovid Therapeutics to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
NEW YORK, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and...
![](https://cdn.snapi.dev/images/v1/2/s/conf17-2042793.jpg)
Ovid Therapeutics to Participate in Upcoming September Investor Conferences
NEW YORK, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and ...
![](https://cdn.snapi.dev/images/v1/5/h/press19-2007128.jpg)
Ovid Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Updates
NEW YORK, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare epilepsies...
![](https://cdn.snapi.dev/images/v1/t/d/conf7-1998620.jpg)
Ovid Therapeutics to Present at the BTIG Virtual Biotechnology Conference 2023
NEW YORK, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and ...
![](https://cdn.snapi.dev/images/v1/u/u/press13-1951136.jpg)
Ovid Therapeutics Expands Its Scientific Leadership Team & Appoints Chief Strategy Officer
NEW YORK, June 28, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare epilepsies...
![](https://cdn.snapi.dev/images/v1/r/c/press5-1947470.jpg)
Ovid Therapeutics Added to Russell 3000® Index
NEW YORK, June 26, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of...